Conclusion The patient was treated with Imiquimod 5% cr. for 8 weeks with non significant results an partial vulvectomy (willingness of the patient) was performed.

A REMINDER FROM THE GREAT IMITATOR – GUMMATOUS SYPHILIS OF THE NASAL CAVITY WITH SEPTAL PERFORATION

A CASE OF DIFFICULT DIAGNOSIS: NEUROSYPHILIS IN HIV INFECTED PATIENTS

Introduction Gummatous syphilis presenting as nasal septal perforation is well described in the classic literature, but rarely encountered in the current antibiotic era. We present a man with a destructive nasal process with a delayed diagnosis of tertiary (late benign) syphilis.

Case Description A 45 year old Eritrean gentleman presented with an ulceroc-nodular lesion of the left nares, progressive over the previous six months. He denied trauma or illicit drug inhalation. Exam was remarkable for left nasal cavity with an eroding destructive lesion perforating through the nasal septum and left nasal ala. He had no clinical signs or symptoms of neurosyphilis. Multiple biopsies revealed acute-on-chronic inflammation with focal necrosis and no evidence of malignancy. Fungal, treponemal and routine bacterial stains were negative, and tissue cultures were negative. Imaging indicated no bony destruction. The patient was treated for presumed cellulitis with multiple courses of oral antibiotics (cephalexin, amoxicillin) with no improvement in symptoms. At follow up, the patient tested negative for human immunodeficiency virus (HIV) infection and negative for anti-neutrophil cytoplasmic antibodies (ANCA). Serologic tests for syphilis were ultimately performed, revealing a rapid plasma reagin (RPR) titer of 1:512 with a reactive florescent treponemal antibody absorption test (FTA-ABS). A CSF evaluation was normal, with no pleocytosis and normal protein and glucose. Treatment was initiated with benzathine penicillin G, three doses of 2.4 million units each at one-week intervals. Clinical response to treatment is pending at the time of this report.

Discussion Gummatous syphilis is of clinical importance because of its potential for local destruction and disfigurement of the nasal structures. Early recognition and management has important individual and public health implications and this case would remind contemporary physicians that “the great imitator” could lurk behind unusual presentations.

Abstracts

DDE RESISTANCE MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2) STRAINS FROM PATIENTS IN GHANA

Introduction The Human Immunodeficiency virus (HIV) epidemic is characterised by the dominance of HIV type 1 (HIV-1) worldwide. Consequently, antiretroviral therapy (ART) and drug resistance studies have focused almost exclusively on HIV-1. In Ghana both HIV-1 and HIV-2 co-circulate with lack of data on HIV-2 drug resistance mutations. We sought to determine drug resistance mutations in HIV-2 patients in Ghana.

Method We used purposive sampling to collect blood from 16 consented patients confirmed as HIV-2 and dual HIV-1/2 by serology and molecular assays. Real-time RT-PCR assay was used to determine the viral load of patients by using an HIV-2 RNA International Standard from the National Institute for Biological Standards and Control (NIBSC). Nucleic acid (RNA and DNA) were extracted from plasma and peripheral blood mononuclear cells (PBMC) respectively. The reverse transcriptase (RT) and protease (PR) genes of HIV-2 were amplified and DNA) were extracted from plasma and peripheral blood mononuclear cells (PBMC) respectively. The reverse transcriptase (RT) and protease (PR) genes of HIV-2 were amplified